BTKi in R/R CLL and MCL

CME

A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 16, 2022

Expiration: December 15, 2023

Othman Al-Sawaf
Othman Al-Sawaf, MD
Matthew S. Davids
Matthew S. Davids, MD, MMSc
Toby A Eyre
Toby A Eyre, MBChB, MD
Christopher R. Flowers
Christopher R. Flowers, MD, MS
Brad S. Kahl
Brad S. Kahl, MD
Kami Maddocks
Kami Maddocks, MD
Anthony Mato
Anthony Mato, MD, MSCE
Lydia Scarfò
Lydia Scarfò, MD
Julie M. Vose
Julie M. Vose, MD

Activity

Progress
1
Course Completed

In this module, 9 hematology experts examine key studies in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), presented at the 2022 Annual Meetings of the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), Pan Pacific Lymphoma Conference, the European Society for Medical Oncology, and the Society of Hematologic Oncology (SOHO).

Please note that the slide thumbnails in this activity link to a highlights PowerPoint slideset covering the studies discussed by the faculty. This slideset may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with CLL and MCL do you provide care for in a typical month?

The results of the CAPTIVATE and GLOW trials support which of the following combinations in the frontline setting for CLL?

Which of the following next-generation BTK inhibitors has shown activity in patients with CLL and disease progression on ibrutinib due to the appearance of a BTK C481 resistance mutation?

Which of the following patients with MCL would be eligible for enrollment on the phase III BRUIN-MCL-321 trial?